Cilostazol and peripheral arterial disease

被引：3
|
作者：
Pearce, Lyndsay [1 ]
Ghosh, Jonathan [1 ]
Counsell, Andrew [1 ]
Serracino-Inglott, Ferdinand [1 ]
机构：
[1] Manchester Royal Infirm, Dept Vasc & Endovasc Surg, Manchester M13 9WL, Lancs, England
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2008年 / 9卷 / 15期
关键词：
cilostazol; claudication; peripheral arterial disease; pletal;
D O I：
10.1517/14656566.9.15.2683
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Peripheral arterial disease is both common and disabling. Contemporary management of peripheral arterial disease is multimodal, encompassing both medical and interventional treatments. Cilostazol (Pletal (TM)), a 2-oxoquinolone derivative, is currently licensed in the UK for the treatment of patients with intermittent claudication to improve their walking distance in the absence of tissue necrosis or rest pain. The therapeutic effects of cilostazol are thought to be mediated through antiplatelet, anti-proliferative and vasodilatory activities. This review aims to provide an overview of the management of peripheral arterial disease focusing upon cilostazol pharmacotherapy.
引用
收藏
页码：2683 / 2690
页数：8
相关论文
共 50 条
  • [1] Cilostazol for peripheral arterial disease
    Robless, P.
    Mikhailidis, D. P.
    Stansby, G. P.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (01):
  • [2] Cilostazol for peripheral arterial disease
    Robless, P.
    Mikhailidis, D. P.
    Stansby, G. P.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01):
  • [3] The role of cilostazol for peripheral arterial disease
    Amendt, K.
    Hsu, E.
    Gomer, M.
    Ruemenapf, G.
    [J]. GEFASSCHIRURGIE, 2008, 13 (03): : 171 - +
  • [4] Management of peripheral arterial disease in the elderly: focus on cilostazol
    Falconer, Travis M.
    Eikelboom, John W.
    Hankey, Graeme J.
    Norman, Paul E.
    [J]. CLINICAL INTERVENTIONS IN AGING, 2008, 3 (01) : 17 - 23
  • [5] CILOSTAZOL NO IMPROVES STRESS OXIDATIVE IN PERIPHERAL ARTERIAL DISEASE
    Bernal Lopez, M.
    Pena, D.
    Gomez-Martin, P.
    Tinahones, F. J.
    Gomez Huelgas, R.
    [J]. ATHEROSCLEROSIS, 2014, 235 (02) : E265 - E265
  • [6] The Effects of Cilostazol on Peripheral Neuropathy in Diabetic Patients With Peripheral Arterial Disease
    O'Donnell, Mark E.
    Badger, Stephen A.
    Sharif, Muhammed Anees
    Makar, Ragai R.
    Young, Ian S.
    Lee, Bernard
    Soong, Chee V.
    [J]. ANGIOLOGY, 2008, 59 (06) : 695 - 704
  • [7] The use of cilostazol in intermittent claudication in patients with peripheral arterial disease
    Wierzchowski, Pawel
    Migdalski, Arkadiusz
    Jawien, Arkadiusz
    [J]. ACTA ANGIOLOGICA, 2014, 20 (03): : 101 - 105
  • [8] The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease
    O'Donnell, Mark E.
    Badger, Stephen A.
    Sharif, Mohammed A.
    Young, Ian S.
    Lee, Bernard
    Soong, Chee V.
    [J]. JOURNAL OF VASCULAR SURGERY, 2009, 49 (05) : 1226 - 1234
  • [9] Cilostazol for peripheral arterial disease could reduce stroke risk?
    Watson, A.
    Mikhailidis, D. P.
    Stansby, G.
    [J]. THROMBOSIS RESEARCH, 2013, 132 (02) : 149 - 150
  • [10] The Vascular and Biochemical Effects of Cilostazol in Diabetic Patients With Peripheral Arterial Disease
    O'Donnell, Mark E.
    Badger, Stephen A.
    Sharif, Muhammad A.
    Makar, Ragai R.
    Young, Ian S.
    Lee, Bernard
    Soong, C. V.
    [J]. VASCULAR AND ENDOVASCULAR SURGERY, 2009, 43 (02) : 132 - 143
12345